Overview
Overview
KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects[1][2]. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements. Reconstitute: Add 3.0 mL bac
- Category
- Healing
- Routes
- subcutaneous
Mechanism
KPV
Mechanism of action
Mechanism of action
KPV works differently from most anti-inflammatory compounds. Instead of broadly suppressing the immune system the way steroids do, it targets a specific inflammation switch inside cells. The mechanism is unusually well mapped for a peptide that has not been tested in humans. PepT1 is a transporter on the surface of intestinal cells that moves di- and tripeptides from the gut into the cell. KPV is small enough to fit. Inflamed gut tissue produces more PepT1, so oral KPV may preferentially concentrate where inflammation is worst (Dalmasso et al. 2008, Gastroenterology). NF-kB is the master switch that turns on inflammatory gene expression. Preclinical work reports that KPV reduces how long this switch stays "on" and how many inflammatory signals are produced — without the broad immunosuppression of corticosteroids. Some older articles claim KPV acts on melanocortin receptors. This is incorrect. The 2008 Dalmasso paper showed no melanocortin-receptor signaling, and follow-up work in receptor-knockout mice confirmed KPV still works without those receptors. KPV does not cause tanning or pigmentation changes and should not be confused with melanotan compounds. Concentrates KPV in inflamed intestinal tissue. Reduces inflammatory gene expression intracellularly. Lowers TNF-driven inflammatory signaling in cell models. Direct activity against S. aureus and C. albicans in lab assays. Bypasses the receptor pathway used by alpha-MSH and melanotan compounds.
Key research findings
- 01
Identity: a tripeptide (lysine-proline-valine) corresponding to the C-terminal three residues of u03b1-melanocyte-stimulating hormone (u03b1-MSH 11u201313).
- 02
In vitro: studies report anti-inflammatory activity, including reduced pro-inflammatory signaling (e.g., NF-u03baB pathway) in immune and epithelial cells.
- 03
Animal model: models of intestinal inflammation (e.g., colitis) report reduced inflammation markers with KPV.
- 04
In vitro / animal model: cellular uptake via peptide transporters (PepT1) in intestinal epithelium is reported, supporting interest in oral/local-delivery research.
- 05
In vitro: unlike full u03b1-MSH, KPV is reported in some studies to retain anti-inflammatory activity without melanocortin-receptor-driven pigmentary activity.
Primary source: No completed human trial Dalmasso et al. 2008 (Gastroenterology): Oral KPV reduced colitis severity in DSS and TNBS mouse models. Identified PepT1-mediated uptake as the central mechanism. Xiao et al. 2017 (Molecular Therapy): Nanoparticle-delivered KPV improved targeting to inflamed colonic tissue and reduced inflammatory markers in DSS colitis. Kannengiesser et al. 2008: Dose-dependent suppression of TNF-driven inflammatory signaling in bronchial epithelial cell models. Catania et al. 2000: Reported direct antimicrobial activity against S. aureus and C. albicans in lab assays. Brzoska, Luger, Maaser et al. 2008: Review of alpha-MSH-derived peptides as a class, including KPV's place in melanocortin-system research. Getting et al. 2006: Reviewed melanocortin-derived anti-inflammatory pharmacology and confirmed KPV's distinction from receptor-mediated signaling.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation[3].
Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability[4].
Wound healing suppo
Protocol Reference
Protocol reference
Commonly cited research range: 200–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Subcutaneous, once daily (community protocol)
200–500 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Subcutaneous, once daily (community protocol) | 200–500 mcg | 4–10 units (0.04–0.10 mL) |
Titration protocol
- Ongoing (no week-by-week ladder)Start200–500 mcg SubQ
Often once daily; community schedules often run several weeks followed by a review period. If a dose is missed, resume the normal schedule at the next dose rather than doubling. KPV is dosed in mcg — label vials clearly when handled alongside mg-dosed peptides to avoid 1,000x draw errors.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Wipe the vial stopper with alcohol and let it dry.
- 02🧴Draw 2 mL bacteriostatic water into a sterile syringe — this 10 mg vial yields 5 mg/mL.
- 03💉Direct the water against the inside of the vial wall, not onto the powder.
- 04💧Allow gentle flow; do not force pressure.
- 05🔄Roll the vial gently for 30–60 seconds; shaking can damage the peptide.
- 06🏷️Inspect: solution should be clear and colorless; discard cloudy, particulate, or off-color solutions.
- 07❄️Label with the concentration (5,000 mcg/mL) and date; refrigerate per product/laboratory instructions.
- 08💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light [6] [7] .
Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days [7] .
Allow vials to reach room temperature before opening to minimize condensation uptake.
Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed [6] .
Clinical Evidence
Clinical evidence
Preclinical models report reduced inflammation in gut and skin tissue; human clinical data are limited.
No completed human trial Dalmasso et al. 2008 (Gastroenterology): Oral KPV reduced colitis severity in DSS and TNBS mouse models. Identified PepT1-mediated uptake as the central mechanism. Xiao et al. 2017 (Molecular Therapy): Nanoparticle-delivered KPV improved targeting to inflamed colonic tissue and reduced inflammatory markers in DSS colitis. Kannengiesser et al. 2008: Dose-dependent suppression of TNF-driven inflammatory signaling in bronchial epithelial cell models. Catania et al. 2000: Reported direct antimicrobial activity against S. aureus and C. albicans in lab assays. Brzoska, Luger, Maaser et al. 2008: Review of alpha-MSH-derived peptides as a class, including KPV's place in melanocortin-system research. Getting et al. 2006: Reviewed melanocortin-derived anti-inflammatory pharmacology and confirmed KPV's distinction from receptor-mediated signaling.
- 01Identity: a tripeptide (lysine-proline-valine) corresponding to the C-terminal three residues of u03b1-melanocyte-stimulating hormone (u03b1-MSH 11u201313).
- 02In vitro: studies report anti-inflammatory activity, including reduced pro-inflammatory signaling (e.g., NF-u03baB pathway) in immune and epithelial cells.
- 03Animal model: models of intestinal inflammation (e.g., colitis) report reduced inflammation markers with KPV.
- 04In vitro / animal model: cellular uptake via peptide transporters (PepT1) in intestinal epithelium is reported, supporting interest in oral/local-delivery research.
- 05In vitro: unlike full u03b1-MSH, KPV is reported in some studies to retain anti-inflammatory activity without melanocortin-receptor-driven pigmentary activity.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to KPV.
- 01Journal of Pharmaceutical Drug Delivery Research (2022) — Pawar K. et al.: KPV as an α‑MSH fragment retains potent anti‑inflammatory activity without melanotropic side effects View Sourceet al. (2022)
- 02FASEB Journal (2003) — Brzoska T. et al.: α‑MSH and related tripeptides: modulation of colitis, inflammation, and melanocortin receptors View Sourceet al. (2003)
- 03Gastroenterology (2008) — Dalmasso G. et al.: PepT1‑mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models View Sourceet al. (2008)
- 04Innerbody Research (2025) — KPV peptide benefits, safety, and administration routes; subcutaneous injection for systemic therapy View Sourceet al. (2025)
- 05Peptides.org Dosage Guide (2023) — KPV dosage calculator and protocol: 200–400 mcg subcutaneously once daily for inflammation and wound healing View Sourceet al. (2023)
- 06Bachem (Peptide Handling Guidelines) — Long‑term peptide stability best achieved in lyophilized form at <−15 °C; avoid extended storage in solution View Source
- 07PeptideSciences (Storage Guidelines) — Lyophilized peptides stable for short‑term at 4 °C, long‑term at −20 °C; reconstituted solutions refrigerated up to ~30 days View Source
- 08Johns Hopkins Arthritis Center — Subcutaneous injection technique: site preparation, needle angle (45–90°), and injection site rotation View Source
- 09NCBI Bookshelf (Clinical Procedures) — Best practices for injection: aseptic technique, site preparation, and administration procedures View Source
- 10PeptideDosages.com (KPV 10mg Protocol) — Reconstitution in 3 mL yields 3.33 mg/mL; unit/mL conversions; precision syringe recommendations for low volumes View Source
- 11CDC Vaccine Administration — Subcutaneous injection route guidance: needle angle, site selection, and no aspiration for subcut injections View Source
- 12PMC (Subcutaneous Drug Injection Review) — Pharmacologic and physiologic considerations of the subcutaneous route for drug administration View Source
- 13Pure Lab Peptides — KPV (10 mg) product page: quality documentation, batch COAs, and research‑grade peptide supplier View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
- KPV is researched mainly for anti-inflammatory and gut-barrier models. Because no human trial has been completed, eligibility framing is conservative.
- Generally outside research-planning scope: pregnancy and breastfeeding (no safety data), known hypersensitivity to peptide compounds, and active complex infectious disease without clinician oversight (because of overlapping inflammatory and antimicrobial signaling).
- Caution areas: active autoimmune disease on prescribed immunomodulators (the interaction has not been studied), and IBD or other inflammatory bowel conditions managed with prescription therapy. KPV should not replace prescribed medication and should be discussed with the treating clinician.
- Quality-control caution: KPV is sold as research-use peptide outside FDA-approved channels. Source quality, COA verification, and storage handling vary widely between suppliers.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| KPVthis | A C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) studied for anti-inflammatory activity, proposed to act through intracellular pathways (e.g., NF-kB modulation) without melanocortin pigmentary activity. | subcutaneous | Investigational / RUO |
| LL-37 | The sole human cathelicidin-derived cationic antimicrobial peptide (37 residues), studied for broad-spectrum antimicrobial activity, immune modulation, and roles in wound healing and angiogenesis. | subcutaneous | Investigational / RUO |
| MGF | A splice variant of IGF-1 (IGF-1Ec) produced in response to mechanical stress; its unique C-terminal E-peptide is studied for activation of muscle satellite cells and tissue repair. | subcutaneous | Investigational / RUO |
| PEG MGF | A pegylated form of mechano growth factor designed for extended stability and systemic half-life; the C-terminal E-peptide is studied for satellite-cell activation and muscle repair. | subcutaneous | Investigational / RUO |
| PNC-27 | A synthetic peptide combining an HDM-2-binding domain with a membrane-penetrating sequence, studied for selective membrane disruption of cancer cells displaying surface HDM-2. | subcutaneous | Investigational / RUO |
| L-Carnitine | An amino acid derivative essential for transporting long-chain fatty acids into mitochondria for beta-oxidation and energy production. | subcutaneous | Investigational / RUO |
| Livagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) studied for peptidase modulation and epigenetic/chromatin effects (e.g., heterochromatin decondensation) in aging cell models. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the C-terminus of alpha-MSH, the body's natural anti-inflammatory hormone. It is researched mainly for anti-inflammatory and gut-barrier effects and skips the melanocortin-receptor pathway used by melanotan compounds.
Preclinical and laboratory research has reported anti-inflammatory effects (especially in colitis and IBD models), antimicrobial activity against S. aureus and C. albicans, and skin-inflammation effects in animal and cell studies. No completed human trial has confirmed these effects in people.
The most-discussed range is 200-500 mcg daily, used either orally or subcutaneously. Some protocols extend up to 1,000 mcg daily, but this is not better supported than the standard range. No completed human dose-finding trial defines an official dose.
A common setup is 10 mg of lyophilized KPV with 2 mL of bacteriostatic water, giving a concentration of 5,000 mcg/mL. At that concentration, a 500 mcg dose equals 0.10 mL or 10 units on a U-100 insulin syringe. The full vial × BAC matrix is in the reconstitution section .
Yes. Oral KPV is a common research route, especially for gut-focused work, because KPV is absorbed through the PepT1 transporter in the small intestine. Oral protocols are typically taken on an empty stomach to reduce competition from dietary peptides.
Community reports are usually mild: transient injection-site irritation, occasional mild headache, and occasional GI discomfort at higher oral doses. Long-term safety is not established because no completed human trial has been published.
No. KPV does not bind the melanocortin receptors that drive melanotan-style pigmentation. It is generally modeled as non-pigmenting and should not be confused with melanotan compounds.
No. KPV is not FDA-approved. On April 22, 2026 the FDA removed KPV from Category 2 because the nomination was withdrawn. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to consult on KPV acetate and KPV free base on July 23, 2026 for potential inclusion on the 503A bulks list. Removal from Category 2 is not the same as FDA approval.
KPV and BPC-157 target different problems. KPV is studied for reducing inflammation through NF-kB inhibition. BPC-157 is studied for tissue repair through angiogenesis and protective signaling. They are commonly paired in gut-focused research stacks because the targets are complementary rather than overlapping.
The most common research-grade lyophilized vial sizes are 5 mg and 10 mg. Some suppliers offer larger vials, but 5 mg and 10 mg dominate research-use SKUs.
Store reconstituted KPV refrigerated at 35.6-46.4F (2-8C), protect it from light, and use within about 30 days. Do not freeze the reconstituted solution. Lyophilized powder is stable at -4F (-20C) for long-term storage.
No. This page is an educational research reference. KPV is not FDA-approved, no completed human trial defines an optimal dose, and nothing on this page should replace consultation with a licensed clinician. Treat the dose ranges shown as research-context references, not as recommendations.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.